Scott M Rocklage Ph.D. is a managing partner at 5 AM Ventures with over two decades of experience in healthcare management. Scott Rocklage has been a strategic leader responsible for the FDA approval of three new drug applications (Omniscan, Teslascan and Cubicin) which has led to 6 new candidates being entered into clinical trials.

Dr. Rockalge received his Bachelors from the University of California, Berkeley in Chemistry and his Ph.D. from the Massachusetts Institute of Technology in Chemistry where he was instrumental in researching Richard R. Schrock’s (2005 Nobel Prize in Chemistry) laboratory. Dr. Rockalge impressive record as an inventor and co-inventor is remarkable with over 30 U.S patents and he has over 100 peer-reviewed publications. Learn more about Scott Rocklage: and

Scott Rocklage’s Work Experience

In 2003, Dr. Rocklage joined 5 AM Ventures as a Venture Partner before becoming a Managing Partner in 2004. In his past, Dr. Rocklage has had the privilege of working for numerous companies within the pharmaceutical industry.

Having served as Chairman and CEO of Cubist Pharmaceuticals and President and CEO of Nycomed Salutar, Dr. Rockalge has also held research and development positions at Salutar and Catalytica.

His other positions held includes being a former Board Chairman of Relypsa and Novira and he currently serves as on the Board as Chairman of Rennovia, Kinestral and Cidara. As well as being on the Boards of Epirus and Pulmatrix, Dr. Rocklage was also a former Executive Chairman of Ilypsa, Miikana and Semprus.

A Day in the life of Scott Rocklage

A typical day for Dr. Rockalge is not typical at all. His various day to day activities could include taking Board meetings to researching science to working with the company’s portfolio management team. Ideas are brought to life by working with business executives, scientists or physicians with the goal in mind to produce new medications that will treat future medical needs.

One area that is currently experiencing growth is the ability to treat cancer by targeting specific mutations, and this breakthrough is already leading to life extending and technologies that will only develop and improve in the near future.